Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results–Medicare data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results–Medicare data

Published:2022-10 Issue:10 Volume:28 Page:1149-1160
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Sundaram Murali¹,Song Yan²,Rogerio Jaqueline Willemann¹³,Zhang Su²,Bhattacharya Rituparna¹,Adejoro Oluwakayode¹⁴,Carley Christopher²,Zhu Jing Jing²⁵,Signorovitch James²,Haas Naomi B⁶

Affiliation:

1. Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ.

2. Analysis Group, Inc., Boston, MA.

3. Exelixis Inc., Alameda, CA.

4. Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA.

5. Student at School of Medicine, Washington University, St Louis, MO.

6. Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference34 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer Statistics, 2021

3. Epidemiology of Renal Cell Carcinoma

4. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of clear cell renal cell carcinoma ≤ 4cm: visual assessment of ultrasound characteristics versus ultrasonographic radiomics analysis;Frontiers in Oncology;2024-07-23

2. Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort;BJUI Compass;2024-06-10

3. Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups;Cancer Medicine;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3